Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Summary
The purpose of this phase I/II, open label, multi-center study is to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options in each indication and therefore will be patients for whom a clinical trial is appropriate.
General Information
NCT#: NCT03829501
Study ID: KY1044-CT01
Trial Phase: Phase I/II
Trial Sponsor: Kymab Ltd.
Therapies Used in This Trial: Atezolizumab, KY1044